X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Unichem Lab with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

UNICHEM LAB vs NATCO PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    UNICHEM LAB NATCO PHARMA UNICHEM LAB/
NATCO PHARMA
 
P/E (TTM) x 285.1 10.8 2,640.6% View Chart
P/BV x 0.7 2.9 22.7% View Chart
Dividend Yield % 2.6 1.5 167.3%  

Financials

 UNICHEM LAB   NATCO PHARMA
EQUITY SHARE DATA
    UNICHEM LAB
Mar-18
NATCO PHARMA
Mar-18
UNICHEM LAB/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs3821,080 35.4%   
Low Rs234671 34.9%   
Sales per share (Unadj.) Rs116.3592.1 19.6%  
Earnings per share (Unadj.) Rs-18.9188.4 -10.0%  
Cash flow per share (Unadj.) Rs-11.7206.3 -5.7%  
Dividends per share (Unadj.) Rs5.008.25 60.6%  
Dividend yield (eoy) %1.60.9 172.3%  
Book value per share (Unadj.) Rs381.0833.6 45.7%  
Shares outstanding (eoy) m70.3436.90 190.6%   
Bonus/Rights/Conversions BBIS-  
Price / Sales ratio x2.61.5 179.1%   
Avg P/E ratio x-16.34.6 -350.3%  
P/CF ratio (eoy) x-26.24.2 -618.3%  
Price / Book Value ratio x0.81.1 77.0%  
Dividend payout %-26.44.4 -603.5%   
Avg Mkt Cap Rs m21,66832,311 67.1%   
No. of employees `0002.34.8 47.2%   
Total wages/salary Rs m2,0063,256 61.6%   
Avg. sales/employee Rs Th3,587.84,522.5 79.3%   
Avg. wages/employee Rs Th880.0674.0 130.6%   
Avg. net profit/employee Rs Th-583.71,439.0 -40.6%   
INCOME DATA
Net Sales Rs m8,18021,848 37.4%  
Other income Rs m610404 151.0%   
Total revenues Rs m8,79022,252 39.5%   
Gross profit Rs m-1,3209,284 -14.2%  
Depreciation Rs m505662 76.3%   
Interest Rs m80154 52.0%   
Profit before tax Rs m-1,2958,872 -14.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m331,920 1.7%   
Profit after tax Rs m-1,3316,952 -19.1%  
Gross profit margin %-16.142.5 -38.0%  
Effective tax rate %-2.621.6 -11.9%   
Net profit margin %-16.331.8 -51.1%  
BALANCE SHEET DATA
Current assets Rs m23,31821,307 109.4%   
Current liabilities Rs m4,6355,920 78.3%   
Net working cap to sales %228.470.4 324.3%  
Current ratio x5.03.6 139.8%  
Inventory Days Days12273 166.2%  
Debtors Days Days121107 114.0%  
Net fixed assets Rs m8,16314,986 54.5%   
Share capital Rs m141369 38.1%   
"Free" reserves Rs m26,66030,353 87.8%   
Net worth Rs m26,80130,760 87.1%   
Long term debt Rs m30-   
Total assets Rs m31,89037,151 85.8%  
Interest coverage x-15.258.6 -25.9%   
Debt to equity ratio x00-  
Sales to assets ratio x0.30.6 43.6%   
Return on assets %-3.919.1 -20.5%  
Return on equity %-5.022.6 -22.0%  
Return on capital %-4.529.3 -15.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m4,35610,322 42.2%   
Fx outflow Rs m02,978 0.0%   
Net fx Rs m4,3567,343 59.3%   
CASH FLOW
From Operations Rs m-1,1234,636 -24.2%  
From Investments Rs m16,487-11,155 -147.8%  
From Financial Activity Rs m-8,8116,509 -135.4%  
Net Cashflow Rs m6,552-18 -36,400.0%  

Share Holding

Indian Promoters % 50.1 52.0 96.3%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 15.1 7.8 192.6%  
FIIs % 3.0 16.6 18.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 31.7 26.0 121.9%  
Shareholders   20,176 25,395 79.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare UNICHEM LAB With:   PFIZER  CADILA HEALTHCARE  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  GLENMARK PHARMA  

Compare UNICHEM LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Downtrend; Sensex Ends 495 Points Lower(Closing)

Indian share markets witnessed most of the selling pressure during closing hours and ended their trading session on a negative note.

Related Views on News

NATCO PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 26.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (down 26.7% YoY). Sales on the other hand came in at Rs 6 bn (down 1.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

UNICHEM LAB Announces Quarterly Results (3QFY19); Net Profit Up 110.9% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, UNICHEM LAB has posted a net profit of Rs 63 m (up 110.9% YoY). Sales on the other hand came in at Rs 2 bn (up 53.8% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

NATCO PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 115.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 115.2% YoY). Sales on the other hand came in at Rs 5 bn (up 27.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

UNICHEM LAB Announces Quarterly Results (2QFY19); Net Profit Down 61.4% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, UNICHEM LAB has posted a net profit of Rs 177 m (down 61.4% YoY). Sales on the other hand came in at Rs 2 bn (down 42.6% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

Stocks that Could Be Out of Reach Post Elections(The 5 Minute Wrapup)

Apr 9, 2019

It's a matter of time before the stocks catch the fancy of the markets and big investors.

3 Indian Stocks with Amazon-Like Potential(Profit Hunter)

Apr 10, 2019

We have identified 3 stocks with huge wealth building potential which meet our 'Click of a Button' criteria.

This Company is Making a Big Comeback and You Can Now Profit from Its Example(The 5 Minute Wrapup)

Apr 10, 2019

How Dell got its mojo back.

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

UNICHEM LAB SHARE PRICE


Apr 22, 2019 03:33 PM

TRACK UNICHEM LAB

  • Track your investment in UNICHEM LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

UNICHEM LAB - SUVEN LIFESCIENCES COMPARISON

COMPARE UNICHEM LAB WITH

MARKET STATS